METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Clinical trials for METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 explained in plain language.
Never miss a new study
Get alerted when new METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 trials appear
Sign up with your email to follow new studies for METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in slowing carcinoid tumors
Disease control OngoingThis study tests a drug called pazopanib in 171 people with carcinoid tumors that are getting worse. The goal is to see if pazopanib can slow or stop tumor growth compared to a placebo. Participants take the drug daily and are monitored for how long their disease stays stable.
Matched conditions: METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Promising drug shows potential to stall neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) better than a placebo. About 298 adults whose cancer worsened after previous treatments will receive either cabozantinib or a dummy pill. The goal is …
Matched conditions: METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC